13.080
13.08 (0%)
As of Dec 20, 2024
Syndax Pharmaceuticals Inc [SNDX]
Source:
Company Overview
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our two lead product candidates are revumenib (SNDX-5613), and axatilimab (SNDX-6352).
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | 781-419-1400 |
| Industry | manufacturing |
| CEO | Michael A. Metzger |
| Website | www.syndax.com |